iShares Nasdaq BioTech ETF

IBB-Q

NASDAQ:IBB

136.49
0.34 (0.25%)

Analysis and Opinions about IBB-Q

Signal
Opinion
Expert
COMMENT
COMMENT
September 20, 2016

Has been a holder in the biotech industry at times through the post crisis period. In a post crisis environment, many of these types of industries tend to do really well. This one is aligned with the health boom and aging demographics. The biggest risk factor today is the US elections. Depending on your view of the US election and where the industry goes, it is a good hold longer-term.

Show full opinionHide full opinion

Has been a holder in the biotech industry at times through the post crisis period. In a post crisis environment, many of these types of industries tend to do really well. This one is aligned with the health boom and aging demographics. The biggest risk factor today is the US elections. Depending on your view of the US election and where the industry goes, it is a good hold longer-term.

BUY
BUY
July 19, 2016

Chart shows a nice jump from mid-June, and should probably continue all the way into November. He understands there are a lot of big health care conferences happening in September, October and November.

Show full opinionHide full opinion

Chart shows a nice jump from mid-June, and should probably continue all the way into November. He understands there are a lot of big health care conferences happening in September, October and November.

WAIT
WAIT
June 20, 2016

Using a 5-year chart, and looking at where the long term support is and their averages, this sector has broken down quite a bit. Wait and see what the new US administration does to this sector. It ran up tremendously for a number of years, and now we are in a correction mode. If Hillary gets her way, there is probably another leg down in this area. You could buy a half or a 3rd just to be in there, because it has corrected significantly from the highs.

Show full opinionHide full opinion

Using a 5-year chart, and looking at where the long term support is and their averages, this sector has broken down quite a bit. Wait and see what the new US administration does to this sector. It ran up tremendously for a number of years, and now we are in a correction mode. If Hillary gets her way, there is probably another leg down in this area. You could buy a half or a 3rd just to be in there, because it has corrected significantly from the highs.

BUY
BUY
June 13, 2016

She likes Biotech’s. They are within the healthcare sector, and by far one of the more attractive industries. There is an enormous amount of double digit growth that we are still expecting from Biotech’s. They are trading rich, but that is because they are growing 2-3 times faster than the rest of the market. Sees this as a safe entry point.

Show full opinionHide full opinion

She likes Biotech’s. They are within the healthcare sector, and by far one of the more attractive industries. There is an enormous amount of double digit growth that we are still expecting from Biotech’s. They are trading rich, but that is because they are growing 2-3 times faster than the rest of the market. Sees this as a safe entry point.

TOP PICK
TOP PICK
June 8, 2016

Biotech’s have gone through a lot of negativity. Seasonally, right around now is when this sector starts to get accumulated by the professionals, because we get into the fall and Christmas area where there is a lot of biotech conferences. Typically, about 70% of all announcements are made somewhere between November and January in Biotechs.

Show full opinionHide full opinion

Biotech’s have gone through a lot of negativity. Seasonally, right around now is when this sector starts to get accumulated by the professionals, because we get into the fall and Christmas area where there is a lot of biotech conferences. Typically, about 70% of all announcements are made somewhere between November and January in Biotechs.

COMMENT
COMMENT
June 3, 2016

In the past few days there has been a huge run up since mid-May, and has bounced off significant support 3 times since February. It is bumping up against resistance of about $290. If it can break above that, it could imply significant upside potential. Chart shows a downward trend line and is currently bumping up against resistance, but shows a nice triple bottom.

Show full opinionHide full opinion

In the past few days there has been a huge run up since mid-May, and has bounced off significant support 3 times since February. It is bumping up against resistance of about $290. If it can break above that, it could imply significant upside potential. Chart shows a downward trend line and is currently bumping up against resistance, but shows a nice triple bottom.

COMMENT
COMMENT
May 10, 2016

Biotech is a very volatile area of the market. This index has options on it. If you are a believer in Biotech, then you are really saying you are a growth investor that has a speculative bent that is looking for a real big move. Rather than paying $250 or so, you might want to think about getting an at the money call option, paying $20, and go for the ride. The worst case scenario is that you will lose $20.

Show full opinionHide full opinion

Biotech is a very volatile area of the market. This index has options on it. If you are a believer in Biotech, then you are really saying you are a growth investor that has a speculative bent that is looking for a real big move. Rather than paying $250 or so, you might want to think about getting an at the money call option, paying $20, and go for the ride. The worst case scenario is that you will lose $20.

PAST TOP PICK
PAST TOP PICK
April 19, 2016

(A Top Pick April 21/15. Down 23.24%.) For 3 years, biotech lead the market. In October last year, virtually the day that Hillary Clinton made comments on drug pricing, it was over. He was stopped out and now has a zero weight in biotechs.

Show full opinionHide full opinion

(A Top Pick April 21/15. Down 23.24%.) For 3 years, biotech lead the market. In October last year, virtually the day that Hillary Clinton made comments on drug pricing, it was over. He was stopped out and now has a zero weight in biotechs.

BUY
BUY
April 6, 2016

Biotech companies in the US. He likes the space. He owns two biotech names individually. He thinks the space is being misunderstood. He thinks there is opportunity here. He likes the look of the chart.

Show full opinionHide full opinion

Biotech companies in the US. He likes the space. He owns two biotech names individually. He thinks the space is being misunderstood. He thinks there is opportunity here. He likes the look of the chart.

COMMENT
COMMENT
March 14, 2016

Feels Biotech would be better than Pharma, as it wouldn’t be a target of the Clinton administration. Thinks big Pharma companies will be closing down their research, and basically outsourcing it to biotech companies. This would be taking a lot of risk, but if you can stomach the volatility it will probably work, and you might get the currency working for you too.

Show full opinionHide full opinion

Feels Biotech would be better than Pharma, as it wouldn’t be a target of the Clinton administration. Thinks big Pharma companies will be closing down their research, and basically outsourcing it to biotech companies. This would be taking a lot of risk, but if you can stomach the volatility it will probably work, and you might get the currency working for you too.

BUY
BUY
September 17, 2015

The biotech space continues to be impressive, when you look at the aging demographics globally and what is happening with the growth in the pipelines in some of these companies. He prefers picking individual names that are growing 20%-25%-30% EPS growth rates. However, this is a great way to own an ETF that will give you the entire sector.

Show full opinionHide full opinion

The biotech space continues to be impressive, when you look at the aging demographics globally and what is happening with the growth in the pipelines in some of these companies. He prefers picking individual names that are growing 20%-25%-30% EPS growth rates. However, this is a great way to own an ETF that will give you the entire sector.

TOP PICK
TOP PICK
September 4, 2015

This has a huge portfolio of lesser-known biotech and pharmaceutical stocks. A little more volatile. Thinks the sector is going to grow quite well. Has been expensive at times, but has sold off recently. A good area if you want to get into the biotechs. With aging population and more money into the healthcare, these guys are going to do very well.

Show full opinionHide full opinion

This has a huge portfolio of lesser-known biotech and pharmaceutical stocks. A little more volatile. Thinks the sector is going to grow quite well. Has been expensive at times, but has sold off recently. A good area if you want to get into the biotechs. With aging population and more money into the healthcare, these guys are going to do very well.

COMMENT
COMMENT
August 31, 2015

Momentum plays. The volatility is three times that of a company like IBM. They need to consolidate. Look to the lows recently for where support might be. The trend of falling highs is the resistance.

Show full opinionHide full opinion

Momentum plays. The volatility is three times that of a company like IBM. They need to consolidate. Look to the lows recently for where support might be. The trend of falling highs is the resistance.

TOP PICK
TOP PICK
August 27, 2015

Everybody should have some biotech in their portfolio. These are companies that develop drugs that help our friends and relatives, and are a very important part of the economy. Extremely volatile. There is probably no other sector out there that will give you such huge potential over such a short period of time. Of the companies with over $500 million market cap, 81% of them are 10% below their 52 week high, and this is a great time to buy it.

Show full opinionHide full opinion

Everybody should have some biotech in their portfolio. These are companies that develop drugs that help our friends and relatives, and are a very important part of the economy. Extremely volatile. There is probably no other sector out there that will give you such huge potential over such a short period of time. Of the companies with over $500 million market cap, 81% of them are 10% below their 52 week high, and this is a great time to buy it.

BUY
BUY
July 3, 2015

Biotech ETF? His pick would be this one. This is a little bit on the high-end, but not unreasonable.

Show full opinionHide full opinion

Biotech ETF? His pick would be this one. This is a little bit on the high-end, but not unreasonable.

Showing 31 to 45 of 66 entries